Back to Research Home
MSAMSA Safety
Health Care · Industrial Specialties · Mid
$182.26−1.18%
As of 23 Oct 2026Mkt cap $7.3B
Stage 13
WATCH
Fundamentals
47.9/75
Technical
10.4/15
Independent
58.2/90
GCAE viewtiming is actionable but business strength/confidence is below BUY requirements
Price
- 1M
- +0.1%
- 3M
- +3.8%
- 6M
- +7.3%
- 1Y
- +10.2%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 22.7xHist median 24.0x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 20.2x
- FCF yield
- 4.9%
Quality
- ROIC
- 16.7%
- Operating margin
- 19.8%
- FCF margin
- 15.8%
- Current ratio
- 3.0x
Growth
- Revenue growth
- +3.7%Latest FY YoY
- Revenue CAGR
- +7.6%
- EPS CAGR
- +90.4%
- FCF CAGR
- +17.4%
Capital
- Share-count trend
- −0.2%3Y annualised
- Net debt
- $475M1.3x OCF
Annual trend
- CAGR 2021–2025
- +7.6%
- Latest · 2025
- $2B
- YoY
- +3.7%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
timing is actionable but business strength/confidence is below BUY requirements
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-02
More details & evidence
Production decision
- Stage 13
- WATCH
- Technical state
- early-recovery
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded